摘要
目的:观察莫沙必利联合聚乙二醇4000散剂治疗慢性功能性便秘的疗效。方法:117例经确诊的慢性功能性便秘患者随机分为3组,治疗组(A组)52例,给予口服莫沙必利5mg/次,3次/天,聚乙二醇4000散剂10g/次,2次/天;对照组又分为B组和C组,B组34例,口服莫沙必利5mg/次,3次/天,C组31例,口服聚乙二醇4000散剂10g/次,2次/天,疗程均为15天。治疗后观察患者大便次数、大便形状及大便困难等症状缓解情况。结果:治疗15天后,3组总有效率分别为94.2%,58.8%,74.2%,治疗组与对照组相比较差异有显著性(P<0.01)。结论:莫沙必利联合聚乙二醇4000散剂治疗慢性功能性便秘疗效满意,不良反应少,是目前治疗功能性便秘的可行方案。
Objective ：To evaluate the therapeutic effect of mesapride citrate combined with macrogol 4000 powder in the treatment of patients with chronic functional constipation.Methods：A total of 117 cases of diagnosed patients with chronic functional constipation were divided into three groups randomly, and each group was given the same course of treatment for 15 days： the treatment group （i.e. gourp A） of 52 cases took orally the mosapride citrate 5 mg per dose, three times a day combined with the macrogol 4000 powder 10 g per dose,two times a day;and the control group＇was subdivided into two groups （i.e. groups B and C）： group B of 34 cases took orally the mesapride citrate 5 mg per dose,three times a day,and group C of 31 cases took orally the macrogol 4000 powder 10 g per dose, two times a day.During the course of treatment,the patients were observed for the alleviation of some symptoms such as the frequency of bowel movement, the stool shape and the difficulty in passing their motions. Then the relevant analyses were made. Results：After the course of treatment for 15 days,the total effective rate of the treatment was 94.2.9% ,58.8% and 74.2% for the three groups respectively. Therefore,there existed remarkable difference in the total effective rate between the treatment group and the control group. Conclusion： The mosapride citrate combined with macrogol 4000 powder method has satisfactory therapeutic effect and less adverse drug reactions in the treatment of patients with chronic functional constipation, and is therefore the feasible method at present for treating the patients with functional constipation.
出处
《现代医药卫生》
2008年第20期3038-3039,共2页
Journal of Modern Medicine & Health
